MicroVision (NASDAQ: MVIS) faces Nasdaq minimum bid-price deficiency notice

Rhea-AI Filing Summary

MicroVision, Inc. reported that it received a deficiency notice from Nasdaq on January 12, 2026 because its common stock failed to meet the minimum bid price requirement of $1 per share for the last 30 consecutive business days under Nasdaq Listing Rule 5450(a)(1). The notice does not immediately affect the listing or trading of its shares, and the company remains in compliance with all other Nasdaq continued listing standards. MicroVision has 180 days from the notice date to regain compliance and is evaluating available options, while its business operations, SEC reporting, and contractual obligations continue unchanged.

Positive

• None.

Negative

• Nasdaq minimum bid-price deficiency notice signals that MicroVision’s stock has traded below the required $1 level for 30 consecutive business days, introducing a risk of future delisting if compliance is not regained within the 180-day window.

Insights

Equity markets and listing standards analyst

Nasdaq bid-price deficiency introduces listing risk but no immediate delisting.

MicroVision has received a Nasdaq notice that its common stock no longer meets the minimum $1 bid price requirement for 30 consecutive business days under Listing Rule 5450(a)(1). This type of notice is common for lower-priced stocks and represents a formal warning rather than an automatic removal from the exchange.

The company’s shares remain listed on Nasdaq, and it is described as being in compliance with all other continued listing standards. The notice explicitly states that business operations, SEC reporting obligations, and contractual commitments are unaffected, so the impact is focused on market perception and potential future trading venue rather than current operations.

MicroVision has 180 days from the January 12, 2026 notice to regain compliance, which typically requires the bid price to close at or above $1 for a specified period. Actual outcomes will depend on future share-price performance and any actions the company chooses to pursue within this compliance window.

false 0000065770 0000065770 2026-01-12 2026-01-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED) January 12, 2026

MicroVision, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-34170		91-1600822
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

18390 NE 68^th Street

Redmond, Washington 98052

(Address of principal executive offices) (Zip code)

(425) 936-6847

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

	☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
	☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
	☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
	☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol(s)		Name of each exchange on which registered
Common stock, par value $0.001 per share		MVIS		The NASDAQ Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On January 12, 2026, MicroVision, Inc. (the “Company”) received a notification letter from The Nasdaq Stock Market (“Nasdaq”) advising that, based upon the closing bid price for the last 30 consecutive business days, the Company no longer meets the continued listing requirement to maintain a minimum bid price of $1 per share, as set forth in Nasdaq Listing Rule 5450(a)(1).

The notification from Nasdaq is only a notification of deficiency, not of imminent delisting, and does not have a current effect on the listing or trading of the Company’s securities on Nasdaq. The Company is currently in compliance with all other Nasdaq continued listing standards. The notification letter does not affect the Company’s business operations, its U.S. Securities and Exchange Commission reporting requirements, or contractual obligations. The Company has 180 days from the date of the notification letter to regain compliance and is considering all available options to do so.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	MICROVISION, INC.
	By:	/s/ Drew G. Markham
		Drew G. Markham
		Senior Vice President, General Counsel and Secretary

Dated: January 16, 2026

FAQ

What did MicroVision (MVIS) disclose in this 8-K filing?

MicroVision disclosed that on January 12, 2026 it received a notification letter from Nasdaq stating the company no longer meets the continued listing requirement to maintain a minimum bid price of $1 per share for 30 consecutive business days under Nasdaq Listing Rule 5450(a)(1).

Is MicroVision (MVIS) being delisted from Nasdaq now?

No. The letter is described as a notification of deficiency and not of imminent delisting, and it does not currently affect the listing or trading of MicroVision’s securities on Nasdaq.

How long does MicroVision have to regain Nasdaq bid-price compliance?

The company has 180 days from the date of the Nasdaq notification letter dated January 12, 2026 to regain compliance with the minimum $1 bid price requirement.

Are MicroVision’s operations or SEC reporting affected by the Nasdaq notice?

The company states that the notification letter does not affect its business operations, its U.S. Securities and Exchange Commission reporting requirements, or its contractual obligations.

Is MicroVision (MVIS) in compliance with other Nasdaq listing standards?

Yes. The company states that it is currently in compliance with all other Nasdaq continued listing standards aside from the minimum bid price requirement.

What actions might MicroVision take to address the Nasdaq deficiency notice?

The filing states that MicroVision is considering all available options to regain compliance within the 180-day period, though it does not specify which actions may be used.